Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Sep 6;32(35):9083-90.
doi: 10.1021/acs.langmuir.6b02227. Epub 2016 Aug 24.

A Fibrous Localized Drug Delivery Platform with NIR-Triggered and Optically Monitored Drug Release

Heng Liu  1 , Yike Fu  1 , Yangyang Li  1 , Zhaohui Ren  1 , Xiang Li  1 , Gaorong Han  1 , Chuanbin Mao  1   2
Affiliations

A Fibrous Localized Drug Delivery Platform with NIR-Triggered and Optically Monitored Drug Release

Heng Liu et al. Langmuir. .

Abstract

Implantable localized drug delivery systems (LDDSs) with intelligent functionalities have emerged as a powerful chemotherapeutic platform in curing cancer. Developing LDDSs with rationally controlled drug release and real-time monitoring functionalities holds promise for personalized therapeutic protocols but suffers daunting challenges. To overcome such challenges, a series of porous Yb(3+)/Er(3+) codoped CaTiO3 (CTO:Yb,Er) nanofibers, with specifically designed surface functionalization, were synthesized for doxorubicin (DOX) delivery. The content of DOX released could be optically monitored by increase in the intensity ratio of green to red emission (I550/I660) of upconversion photoluminescent nanofibers under 980 nm near-infrared (NIR) excitation owing to the fluorescence resonance energy transfer (FRET) effect between DOX molecules and the nanofibers. More importantly, the 808 nm NIR irradiation enabled markedly accelerated DOX release, confirming representative NIR-triggered drug release properties. In consequence, such CTO:Yb,Er nanofibers presented significantly enhanced in vitro anticancer efficacy under NIR irradiation. This study has thus inspired another promising fibrous LDDS platform with NIR-triggered and optics-monitored DOX releasing for personalized tumor chemotherapy.

PubMed Disclaimer

Conflict of interest statement

Notes The authors declare no competing financial interest.

Figures

Figure 1
Figure 1
(a) Schematic diagram of the electrospinning setup. (b) SEM image of as-spun nanofibers. (c) XRD patterns of CTO:Yb,Er nanofibers annealed from 600 to 800 °C. (d) Photoluminescent spectra of CTO:Yb,Er nanofibers sintered at different temperatures (980 nm excitation).
Figure 2
Figure 2
(a) TEM images of CTO:Yb,Er nanofibers sintered at 700 °C. (b, c) HR TEM images of CTO:Yb,Er nanofibers.
Figure 3
Figure 3
(a) FT-IR spectra of DOX drug, CTO:Yb,Er nanofibers (CTO), amino-modified CTO:Yb,Er nanofibers (CTO-NH2), and PAA modified CTO:Yb,Er nanofibers before DOX loading (CTO-PAA) and after DOX loading (CTO-PAA-DOX). (b) Zeta potential of CTO, CTO-NH2, and CTO-PAA nanofibers. (c) The viability of BMSCs incubated with CTO:Yb,Er-PAA nanofibers as a function of fiber concentration for 24 h. (d) TG curves of CTO:Yb,Er nanofibers before and after DOX loading (CTO, CTO-DOX), PAA modified CTO:Yb,Er nanofibers before and after DOX loading (CTO-PAA, CTO-PAA-DOX).
Figure 4
Figure 4
UC emission spectra of CTO:Yb,Er nanofibers (CTO), DOX loaded CTO:Yb,Er nanofibers (CTO-DOX), and PAA modified CTO:Yb,Er nanofibers after DOX loading (CTO-PAA-DOX).
Figure 5
Figure 5
(a) DOX release profile of CTO:Yb,Er-PAA-DOX nanofibers in PBS solutions with different pH values. (b) The UC emission spectra (under the excitation of 980 nm NIR) and (c) enlarged spectra from 480 to 600 nm as a function of release time for CTO:Yb,Er-PAA-DOX nanofibers. (d) The variation of the intensity ratio between 550 and 660 nm spectra (I550/I660) of CTO:Yb,Er-PAA-DOX nanofibers during DOX releasing.
Figure 6
Figure 6
(a, b) DOX release profile of CTO:Yb,Er-PAA-DOX nanofibers with and without laser irradiation (808 nm) in PBS solutions with pH 7.4 and 5.2. (c) Relative HCC viability (to blank control) of CTO:Yb,Er-PAA nanofibers irradiated with an 808 nm laser (CTO-PAA-NIR), CTO:Yb,Er-PAA-DOX nanofibers with (CTO-PAA-DOX-NIR, DOX concentration is 10 μg/mL) and without 808 nm laser irradiation (CTO-PAA-DOX, DOX concentration is 10 μg/mL) from 0 to 48 h (**P < 0.01).
See this image and copyright information in PMC

References

    1. Chang B, Chen D, Wang Y, Chen Y, Jiao Y, Sha X, Yang W. Bioresponsive controlled drug release based on mesoporous silica nanoparticles coated with reductively sheddable polymer shell. Chem Mater. 2013;25(4):574–585.
    1. Parveen S, Misra R, Sahoo SK. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine. 2012;8(2):147–66. - PubMed
    1. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med. 2012;63:185–98. - PubMed
    1. De Souza R, Zahedi P, Allen CJ, Piquette-Miller M. Polymeric drug delivery systems for localized cancer chemotherapy. Drug Delivery. 2010;17(6):365–75. - PubMed
    1. Wolinsky JB, Colson YL, Grinstaff MW. Local drug delivery strategies for cancer treatment: gels, nanoparticles, polymeric films, rods, and wafers. J Controlled Release. 2012;159(1):14–26. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources